Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com Legal provides analysis of legal decisions from federal courts and from the PTAB related to biologics and biosimilars.
-
-
As we previously reported in this post, the Supreme Court granted certiorari in its first biosimilar case on Sandoz’s petition in Sandoz,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. filed a Declaratory Judgment...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. (collectively “Plaintiffs”) filed a Complaint in the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Genentech’s lawsuit against Amgen has come to a quick (although perhaps temporary) end, with the Court dismissing Genentech’s complaint...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Inter partes review (“IPR”) is one of several post-grant procedures created by the Leahy Smith America Invents Act (“AIA”). An...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On February 15, 2017, Genentech filed litigation accusing Amgen of violating the Biologics Price Competition and Innovation Act...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]